Evaluation Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing and Targeted Treatment Strategies Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Cathy Eng, MD, FACP, FASCO 5 4 3 2 1 David H. Ilson, MD, PhD 5 4 3 2 1 Nataliya Uboha, MD, PhD 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Evaluate the role of new and emerging biomarkers in the pathophysiology of gastric and GEJ cancer 5 4 3 2 1 Integrate biomarker testing and guideline recommendations for genomic profiling into treatment selection strategies 5 4 3 2 1 Assess the mechanisms and clinical efficacy and safety data of current and emerging targeted agents for the treatment of gastric and GEJ cancer 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with gastric cancer on a monthly basis? 10 or fewer 20 30 40 50 or more Based on my participation in this activity, I anticipate I will more often: (select all that apply) Assess the role of new and emerging biomarkers for gastric/GEJ cancer Utilize biomarker testing to inform diagnosis, prognosis, and treatment selection in gastric/GEJ cancer Integrate guideline recommendations for biomarker testing in clinical practice Remain appraised of current and emerging targeted agents for the treatment of gastric and GEJ cancer Incorporate new and emerging agents into gastric/GEJ cancer care, when applicable Evaluate the clinical efficacy and safety data of current and emerging targeted agents for the treatment of gastric and GEJ cancer Other (please specify): Please now rate your ability to use currently available therapies to manage gastric cancer. Excellent Very Good Good Fair Poor Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Previous
